Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
lonigutamab (VB421) / Pierre Fabre, ACELYRIN
TED, NCT05683496: Efficacy and Safety of Lonigutamab in Subjects with Thyroid Eye Disease	Recruiting	1/2	54	US, RoW	lonigutamab, Placebo	ACELYRIN Inc.	Thyroid Eye Disease	05/25	05/25